Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Study:

A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Rationale:

n/a

Purpose:

The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Pancreatic Cancer Drug: AVN944 Phase 2

Verified by Vertex Pharmaceuticals Incorporated September, 2013

Sponsored by: Vertex Pharmaceuticals Incorporated
Information provided by: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov identifier: NCT00493441

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic - Taussig Cancer Center
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site